graphic of a breast cancer cell
UCL has been named as a centre of excellence by national blood cancer charity Leukaemia & Lymphoma Research. The charity has invested £8.7 million in projects at UCL, which conducts world-class research into all the main blood cancers - leukaemia, lymphoma and myeloma. UCL researchers and their colleagues at the Royal Free Hospital in Hampstead ? part of UCL Partners, Europe's largest academic health science partnership ? are exploring how to harness the immune system to fight blood cancer. Their work includes the development of treatments that engineer the patients? own white blood cells to target and kill leukaemia cells in the body. A recent example of this, called 'TCR gene therapy', is likely to be important for patients who do not respond to standard chemotherapy and two new trials using the method are due to start this year. Naming the UCL Cancer Institute in Huntley Street as its first national centre of excellence is part of the charity's plans to focus investment in leading research institutions across the UK. Dr David Grant, Scientific Director of Leukaemia & Lymphoma Research, said: "UCL houses some truly world-class research into blood cancers.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
